NASS 2018 Annual Meeting

Robert Eastlack, MD




Board of Directors: Matrisys (Board of Director position), Nocimed (25,000 Shares, 0.50%, 25000 stock options), San Diego Spine Foundation (None), SOLAS (None), Spine Innovations, (Director); Consulting: Aesculap (B), Carevature (A), Medtronic (None), NuVasive (D), SeaSpine (C), SI Bone (C, Paid directly to institution/employer), Stryker (C), Titan (B); Fellowship Support: AO (None, Educational support for the fellows), NuVasive (E, Paid directly to institution/employer), SeaSpine (D, fellowship support); Grants: Scripps Clinic Medical Group (C, Paid directly to institution/employer); Private Investments: Nocimed (<1%), SeaSpine (<1%), Top Doctors Labs (None), Top Doctors Labs (1 Shares, 100%, Owner/CEO); Research Support (Staff and/or materials): NuVasive (C, Paid directly to institution/employer); Royalties: Aesculap (B), Globus Medical (B), NuVasive (B), SeaSpine (A); Scientific Advisory Board: Aesculap (B), Clearview (B); Stock Ownership: Alphatec (<1%), NuVasive (< 1%), SeaSpine (<1%), Spine Innovations (None, 100,000 Shares, 15%, Co-founder).

Sessions :